2023
Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A).
Atkins M, Jegede O, McDermott D, Haas N, Bilen M, Stein M, Sosman J, Plimack E, Alter R, Ornstein M, Hurwitz M, Peace D, Einstein D, Catalano P, Hammers H, Regan M. Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A). Journal Of Clinical Oncology 2023, 41: 604-604. DOI: 10.1200/jco.2023.41.6_suppl.604.Peer-Reviewed Original ResearchAdvanced clear cell renal cell carcinomaTreatment-related adverse eventsGrade 3Clear cell renal cell carcinomaActive treatment approachCheckMate 067 trialCheckMate 214 trialFurther anticancer therapyNivolumab/ipilimumabProlonged disease controlPhase II studyCell renal cell carcinomaKaplan-Meier curvesRenal cell carcinomaNivolumab monotherapyStable diseaseEligible patientsProtocol therapyTherapy initiationII studyTherapy cessationAdverse eventsSurvival outcomesCell carcinomaMetastatic melanoma
2020
420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study
Diab A, Tykodi S, Daniels G, Maio M, Curti B, Lewis K, Jang S, Kalinka E, Puzanov I, Spira A, Cho D, Guan S, Puente E, Hoch U, Currie S, Nguyen T, Lin W, Tagliaferri M, Zalevsky J, Sznol M, Hurwitz M. 420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study. Journal For ImmunoTherapy Of Cancer 2020, 8: a256-a256. DOI: 10.1136/jitc-2020-sitc2020.0420.Peer-Reviewed Original ResearchBaseline tumor biopsiesMetastatic melanomaUntreated patientsPD-L1Clinical activityTumor biopsiesFDA breakthrough therapy designationGene expression profilesObjective response ratePD-L1 statusPhase 3 trialProgression-free survivalStage IV melanomaHigher ORRBiomarkers of responseNon-invasive biomarkersUnmet need existsBreakthrough therapy designationInstitutional review boardMedian PFSPrimary endpointDurable responsesComplete responseMore patientsOS rates